(Q37972189)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22206765%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

title

Review of methodological issues of clinical trials in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22206765%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22206765%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

author name string

Xavier Montalban

series ordinal

1

1 reference

26 August 2017

1 December 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22206765%20AND%20SRC:MED&resulttype=core&format=json

Journal of the Neurological Sciences

19 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22206765%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

volume

311 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22206765%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

page(s)

S35-42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22206765%20AND%20SRC:MED&resulttype=core&format=json

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

19 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Secondary progressive multiple sclerosis: current knowledge and future challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

A comparison of observational studies and randomized, controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Randomized, controlled trials, observational studies, and the hierarchy of research designs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Systematic reviews in health care: Assessing the quality of controlled clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

The changing demographic pattern of multiple sclerosis epidemiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Prevalence of multiple sclerosis in Denmark 1950--2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

MRI criteria for MS in patients with clinically isolated syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Will Rogers phenomenon in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Assessing changes in relapse rates in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

MRI measures of neuroprotection and repair in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Freedom from disease activity in multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-510X%2811%2970007-7

10.1016/S0022-510X(11)70007-7

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22206765%20AND%20SRC:MED&resulttype=core&format=json

19 January 2020

1 reference